New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export SBRA’s income statement to Excel — free account
Sabra Healthcare REIT, Inc.
SBRAReal Estate Reit Healthcare Facilities
Sabra Healthcare REIT, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $774.6 million, up 10.2% from fiscal 2024.
- Revenue
- +31.3%
- EPS
- +22.2%
- Free cash flow
- n/m
- Total debt
- −5.99%
Quarter to September 2026, against a year earlier
20.39
0.07
−0.34%
After hours trading: 20.39, unchanged, last trade 4:01pm Eastern.
Follow SBRA
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 1.95% in Q3 FY26, against a low of 1.91% in Q2 FY26.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 5.6% | 5.7% | 2.4% | 2.5% |
| ROIC | 3.0% | 3.0% | 1.9% | 2.0% |
Debt
Net debt is 18.60× a year’s EBITDA. Debt is 0.86× equity, against 0.96× in Q1 FY26.
Debt / equityNet debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.9× | 1.0× | 1.0× | 0.9× |
| Net debt / EBITDA | 21.2× | 21.0× | 98.1× | 18.6× |
Per share, from Q4 FY25
Since Q4 FY25, per share: revenue has grown 12.0%; book value has fallen 5.01%.
RevenueBook value
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | 1.0× | 1.0× | 1.1× | 1.1× |
| Book value | 1.0× | 0.9× | 0.9× | 0.9× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
29.14 | 30.05 | 75.04 | 70.43 |
P/S ratio |
5.90 | 5.96 | 5.73 | 5.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
52.28 | 49.29 | 57.35 | 39.08 | |
P/B ratio |
1.62 | 1.74 | 1.79 | 1.77 | |
Price to Tangible BV |
1.66 | 1.78 | 1.84 | 1.83 | |
EV/Sales |
9.06 | 9.09 | 8.50 | 8.09 | |
EV/EBITDA |
15.83 | 16.30 | 19.96 | 19.09 | |
EV/Operating CF |
20.14 | 20.15 | 19.67 | 18.56 | |
EV/FCF |
(122.74) | (56.23) | (26.37) | (31.38) | |
Quick Ratio |
0.65 | 1.05 | 2.07 | 0.32 | |
Current Ratio |
4.29 | 4.72 | 3.07 | 1.21 | |
Net Debt/EBITDA |
21.25 | 21.00 | 98.14 | 18.60 | |
Debt/Assets |
46.04% | 47.67% | 47.64% | 44.86% | |
Debt/Equity |
0.90 | 0.96 | 0.95 | 0.86 | |
Asset Turnover |
0.14 | 0.15 | 0.16 | 0.17 | |
Operating CF/Net income |
3.21 | 2.41 | (3.41) | 4.51 | |
Capex/Depreciation |
(1.56) | (2.03) | (3.72) | (3.70) | |
Interest Coverage |
2.21 | 2.39 | (1.08) | 2.19 | |
Selling, General and Administrative Expense of Revenue |
7.51% | 6.70% | 7.13% | 6.24% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
1.45% | 1.40% | 1.73% | 1.57% | |
Graham Net Nets |
(0.47) | (0.46) | (0.49) | (0.48) | |
Graham Number |
13.08 | 12.62 | 7.99 | 8.37 | |
Earnings Yield |
3.43% | 3.33% | 1.33% | 1.42% | |
Free Cash Flow Yield |
(1.25%) | (2.71%) | (5.63%) | (4.70%) | |
Revenue per Share |
0.88 | 0.88 | 0.94 | 0.98 | |
Operating CF per Share |
0.36 | 0.39 | 0.34 | 0.50 | |
Capex per Share |
(0.33) | (0.43) | (0.83) | (0.94) | |
Free Cash Flow per Share |
0.03 | (0.04) | (0.49) | (0.43) | |
Cash per Share |
0.32 | 0.49 | 0.94 | 0.17 | |
Shareholders Equity per Share |
11.70 | 11.06 | 10.91 | 11.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.70 | 11.06 | 10.91 | 11.12 | |
Free Cash Flow |
7.36 | (9.59) | (123.92) | (110.74) | |
Working Capital |
392.91 | 438.41 | 238.47 | 28.37 | |
Capital Expenditures |
(80.07) | (107.95) | (209.74) | (239.71) | |
Net Current Asset Value |
(2,157.37) | (2,246.92) | (2,406.75) | (2,425.30) | |
EV/EBIT |
27.37 | 28.77 | 46.63 | 45.42 | |
Capex to Sales |
0.38 | 0.49 | 0.89 | 0.96 | |
Price to Operating Income |
17.82 | 18.88 | 31.40 | 30.80 | |
| Other line items | |||||
Average Payables |
118.61 | 115.01 | 114.01 | 129.52 | |
Average Assets |
5,398.54 | 5,412.19 | 5,420.30 | 5,497.36 | |
Average Common Equity |
2,782.54 | 2,745.07 | 2,731.96 | 2,834.11 |
Columns are period end dates · fundamentals updated Nov 18, 2026